TG Therapeutics Inc (TGTX)
Payables turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cost of revenue | US$ in thousands | 192,784 | 136,837 | 70,219 | 128,302 | 107,850 |
| Payables | US$ in thousands | — | — | — | — | — |
| Payables turnover | — | — | — | — | — |
December 31, 2024 calculation
Payables turnover = Cost of revenue ÷ Payables
= $192,784K ÷ $—K
= —
Based on the provided data, TG Therapeutics Inc payables turnover ratio is not available for the years 2020 to 2024. This ratio is an important metric that indicates how efficiently the company is managing its accounts payable by assessing how quickly the company pays its suppliers.
The absence of this information makes it challenging to evaluate the company's ability to effectively manage and settle its payables, which is an essential aspect of working capital management. Without the payables turnover ratio data, it is difficult to assess the company's liquidity, operational efficiency, and relationships with its suppliers.
A low payables turnover ratio could indicate that the company is taking too long to pay its suppliers, potentially straining relationships or missing out on potential discounts, while a high ratio could suggest aggressive payment practices or potential financial distress.
Therefore, the lack of payables turnover data for TG Therapeutics Inc hinders a comprehensive analysis of its payables management and financial performance in relation to its suppliers.
Peer comparison
Dec 31, 2024